AUSSENDER



Vidac Pharma Holding PLC
Ansprechpartner: Sandra Gamzon
Tel.: +972 544 999951
E-Mail: investors@vidacpharma.com
Pressefach (182)

Rechtsgrundlage

Alle
Insiderinformationen
Unternehmensmitteilungen
Finanzberichte
Stimmrechtsmitteilungen
HV-Bekanntmachungen
Sonstige

Schlagwörter

general meeting
DE EN
04.10.2026 - 10:35 | Vidac Pharma Holding PLC
Results of Annual General Meeting
29.09.2026 - 15:00 | Vidac Pharma Holding PLC
Vidac Pharma Publishes Unaudited Interim Financial Statements for the First Half of 2026
15.09.2026 - 08:40 | Vidac Pharma Holding PLC
Reaches Last Patient Last Visit in Phase 2b Study of VDA-1102 in Actinic Keratosis
08.09.2026 - 19:35 | Vidac Pharma Holding PLC
Notice of Annual General Meeting
31.08.2026 - 08:30 | Vidac Pharma Holding PLC
Publishes 2025 Annual Report and Financial Statements
12.06.2026 - 10:00 | Vidac Pharma Holding PLC
Vidac Pharma meldet Abschluss der Patientenrekrutierung in Phase-2B-Studie mit VDA-1102
13.05.2026 - 10:35 | Vidac Pharma Holding PLC
The Company is in Advanced Negotiations to Join Quest for Health and Expand into Strasbourg
11.03.2026 - 07:00 | Vidac Pharma Holding PLC
Financial Support by Main Shareholders and Directors of Vidac Pharma
16.02.2026 - 07:00 | Vidac Pharma Holding PLC
Vidac Pharma to Present Company Progress at the 19th Annual European Life Sciences CEO Forum
11.02.2026 - 07:00 | Vidac Pharma Holding PLC
initiates in vivo pre-clinical program in psoriasis, expanding its hk2/vdac platform beyond oncology
12.01.2026 - 11:40 | Vidac Pharma Holding PLC
vidac pharma receives notice of issuance from uspto for one of its core patents
17.12.2025 - 12:38 | Vidac Pharma Holding PLC
Vidac Pharma Strengthens Market Liquidity While Advancing Clinical Pipeline
15.12.2025 - 15:00 | Vidac Pharma Holding PLC
Commencement of Trading on Xetra
11.12.2025 - 09:51 | Vidac Pharma Holding PLC
Initiation of Phase 2B* Clinical Trial for Targeted Treatment of Highly Proliferative Actinic Keratosis Lesions
02.12.2025 - 10:27 | Vidac Pharma Holding PLC
Successful Listing in Düsseldorf Stock Exchange's Open Market, Primary Market Segment, and Results of Public Offer
|
99.112 Abonnenten
|
236.424 Meldungen
|
95.762 Pressefotos
|
Folgen Sie uns auf Twitter
|
Persönlicher Kontakt